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In previous studies, we developed and characterised multicompartmental microcapsules as a platform 37 
for the targeted oral delivery of lipophilic drugs in Type 2 diabetes (T2D). We also designed a new 38 
microencapsulated formulation of Probucol-Sodium Alginate (PB-SA), with good structural properties 39 
and excipient compatibility. The aim of this study was to examine the stability and pH-dependant 40 
targeted release of the microcapsules at various pH values and different temperatures. 41 
Microencapsulation was carried out using a Büchi-based microencapsulating system developed in our 42 
laboratory. Using SA polymer, two formulations were prepared: empty SA microcapsules (SA, control) 43 
and loaded SA microcapsules (PB-SA, test), at a constant ratio (1:30) respectively. Microcapsules were 44 
examined for drug content, Zeta-potential, size, morphology and swelling characteristics, and PB 45 
release characteristics at pH 1.5, 3, 6, and 7.8. The production yield and microencapsulation efficiency 46 
were also determined. PB-SA microcapsules had 2.6 ± 0.25% PB content, and Zeta-potential of -66 ± 47 
1.6%, suggesting good stability. They showed spherical and uniform morphology and significantly 48 
higher swelling at pH 7.8 at both 25 oC and 37oC (p<0.05). The microcapsules showed multiphasic 49 
release properties at pH 7.8. The production yield and microencapsulation efficiency were high (85 ± 50 
5 and 92 ± 2 %, respectively). The PB-SA microcapsules exhibited distal gastrointestinal tract targeted 51 
delivery with a multi-phasic release pattern, and with good stability and uniformity. However, the 52 
release of PB from the microcapsules was not controlled, suggesting uneven distribution of the drug 53 
within the microcapsules.    54 
 55 
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Diabetes mellitus is a disease characterized by hyperglycaemia and metabolic disorders. It is classified 73 
as Type 1 diabetes (T1D) or Type 2 diabetes (T2D). T1D is an autoimmune disease marked by the 74 
destruction of -cells of the pancreas resulting in a partial or complete lack of insulin production and 75 
the inability of the body to control glucose homeostasis [1]. T2D develops due to genetic and 76 
environmental factors that lead to tissue desensitization to insulin [2]. Despite strict glycaemic control 77 
and the fact that new and more effective antidiabetic drugs are continuously appearing onto the 78 
market, diabetic patients still suffer from the disease and its complications [3]. Antidiabetic drugs are 79 
effective in minimizing variations between peaks and troughs of blood glucose levels in diabetic 80 
patients [3]. Common antidiabetic drugs include: sulfonylureas, such as Gliclazide that enhances 81 
insulin production, pancreatic β-cell functionality and improves insulin sensitivity; and the biguanide 82 
Metformin, which reduces glucose production in the liver [3]. However, the risks of hypoglycaemia, 83 
free radical and toxin build up remain major issues associated with T2D [4, 5].  Thus, there is an urgent 84 
need for new and more efficacious medications for diabetes that are capable of exerting a stronger 85 
protection of β-cells and have considerable anti-free radical and antioxidant effects. An advantage is 86 
optimising the formulations of drugs that have already shown desirable antidiabetic effects such as 87 
lowering of blood cholesterol and reducing the formation of atherosclerotic plaques. 88 
 89 
Probucol (PB) is a highly lipophilic drug that has been shown to protect β-cells of the pancreas through 90 
its strong anti-free radical and antioxidant effects, and thereby neutralizing reactive oxygen species 91 
and alleviating oxidative stress [6, 7]. PB was developed as an antihyperlipidemic drug, but was 92 
withdrawn in some countries owing to high interindividual variation in absorption and potential 93 
adverse effects [8]. PB has high affinity for adipose tissues and has huge inter- and intra-individual 94 
variations in absorption after an oral dose [9]. The variations in absorption and efficacy are predicted 95 
to contribute significantly to its adverse effects, and compromise its potential clinical benefits in T2D 96 
[10]. Thus, developing a novel and stable formulation with high uniformity, efficient targeted delivery, 97 
and consistent release kinetics is anticipated to overcome these variations and maximise its potential 98 
use in T2D.  99 
 100 
In a recent study carried out in our laboratory (manuscript currently under review), we designed novel 101 
multi-compartmental microcapsules of PB that displayed uniform and homogenous characteristics 102 
and exhibited pseudoplastic-thixotropic properties. These newly designed PB microcapsules showed 103 
good compatibility and structural properties. Accordingly, in this study, we aimed at describing further 104 
the targeted delivery, stability, and release properties of these PB microcapsules. 105 
 106 
Materials and methods 107 
 108 
Materials 109 
Probucol (PB, 99%) and low viscosity sodium alginate (LVSA, 99 %) were purchased from Sigma 110 
Chemical Co, USA. Calcium chloride dihydrate (CaCl2. 2H20, 98%) was obtained from Scharlab S.L, 111 
Australia.  All solvents and reagents were supplied by Merck (Australia) and were of HPLC grade and 112 
used without further purification. 113 
 114 
Drugs preparations 115 
Due to PB being highly insoluble [11] in aqueous media, it was dissolved in 10% freshly prepared 116 
Ultrasonic suspension prior to carrying out of experiments. Stock suspensions of PB (20 mg/mL) were 117 
prepared by adding the powder to 10% Ultrasonice water-soluble gel in 100mL HPLC water. The CaCl2 118 
stock solution (2%) was prepared by adding CaCl2 powder to HPLC water. All preparations were mixed 119 





Preparation of microcapsules 123 
Vibrational-jet flow microencapsulation of PB-loaded LVSA was prepared using a Büchi-390 based-124 
microencapsulating system (BÜCHI Labortechnik, Swizerland). Polymer solutions containing SA with 125 
and without PB were made up to a final concentration of PB-SA in a ratio of 1:30 respectively. 126 
Parameters were set in a frequency range of 1000-1500Hz and a flow rate of 4 mL/min under a 127 
consistent air pressure of 300 mbar. Vibrational-jet flow prepared microcapsules were collected from 128 
the microencapsulating system and, for each formulation, 3 independent batches were prepared and 129 
tested separately (n=3). All microcapsules (unloaded and PB-loaded) were prepared and treated in the 130 
exact same way.  Furthermore, the microcapsules were dried using stability chambers (Angelantoni 131 
Environmental and Climatic Test Chamber, Italy). The weight of the recovered dry particles was then 132 
recorded and the PB contents, production yield, microencapsulation efficiency, zeta potentials, and 133 
mean particle size of each preparation were all measured and compared, as described below. 134 
 135 
Characterization of PB-loaded microcapsules 136 
 137 
Drug content, production yield, microencapsulation efficiency, and stability studies:  138 
Drug content, production yield, and microencapsulation efficiency: 1 g of microcapsules was carefully 139 
weighed, ground, and dissolved in 200 mL of phosphate buffer (pH 7.8) and the suspension was stirred 140 
with a magnetic stirrer for 6 hours. 2 mL of the solution were then transferred to 100 mL flask and 141 
diluted with phosphate buffer (vehicle) to 100 mL. Aliquots of the dissolution medium (2 mL) were 142 
withdrawn at predetermined time points (every 200 seconds) and filtered through a 0.22 μm Millipore 143 
filter. The amount of dissolved drug was determined spectrophotometrically at λMax = 242 nm against 144 
the buffer as blank [12, 13]. The measurements were performed under sink conditions, and average 145 
values were calculated. Absorbance was measured using an UV spectrophotometer (Shimatzu UV-Vis 146 
spectrophotometer 1240, Japan). PB concentrations were calculated from the calibration curve. All 147 
analyses were carried out in triplicate (n=3). Drug contents, production yield, and microencapsulation 148 
efficiency were calculated from the following equations. 149 
 150 
1. %𝑫𝒓𝒖𝒈 𝑪𝒐𝒏𝒕𝒆𝒏𝒕 =
𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑷𝑩 𝒊𝒏 𝒕𝒉𝒆 𝒎𝒊𝒄𝒓𝒐𝒄𝒂𝒑𝒔𝒖𝒍𝒆𝒔
𝑻𝒐𝒕𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒎𝒊𝒄𝒓𝒐𝒄𝒂𝒑𝒔𝒖𝒍𝒆𝒔
 𝒙 𝟏𝟎𝟎 151 
 152 
2. %𝑷𝒓𝒐𝒅𝒖𝒄𝒕𝒊𝒐𝒏 𝒀𝒊𝒆𝒍𝒅 =
𝑻𝒐𝒕𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒉𝒆 𝒎𝒊𝒄𝒓𝒐𝒄𝒂𝒑𝒔𝒖𝒍𝒆𝒔
𝑻𝒐𝒕𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒉𝒆 𝒑𝒐𝒍𝒚𝒎𝒆𝒓 + 𝒅𝒓𝒖𝒈 𝒔𝒐𝒍𝒖𝒕𝒊𝒐𝒏
 𝒙 𝟏𝟎𝟎 153 
 154 
3. % 𝑬𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 =
𝑫𝒓𝒖𝒈 𝒄𝒐𝒏𝒕𝒆𝒏𝒕
𝑻𝒉𝒆𝒐𝒓𝒆𝒕𝒊𝒄𝒂𝒍 𝒄𝒐𝒏𝒕𝒆𝒏𝒕




Zeta-potential and size analysis: To determine the electrokinetic stability and size uniformity of the 159 
microcapsules in the colloidal system, zeta potential and size distribution for the microencapsulated 160 
formulation of SA and PB-SA were measured by photon correlation spectroscopy using a Zetasizer 161 
3000HS (Malvern Instruments, Malvern, UK), and by the Mie and Fraunhofer scattering technique 162 
using a Mastersizer 2000 (Malvern Instruments, Malvern, UK).  The measurements were performed 163 
at 25°C with a detection angle of 90°, and the raw data were subsequently correlated to Z average 164 
mean size using a cumulative analysis via an OmniSEC-Zetasizer software package.  Each sample was 165 
measured 10 times.  All analyses were performed on samples appropriately diluted with filtered 166 
deionized water. All determinations were performed in triplicate and results were reported as mean 167 
 SD. 168 
 169 
Optical microscopy (OM): Morphological characteristics and particle size analysis were determined 170 
utilizing a Nikon YS2-H mounted with a ToupTek photonics FMA050 fixed calibrated microscope 171 
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adaptor (Japan). Sample analysis was carried out in triplicates. Briefly, pre-determined quantities (10 172 
microcapsules from each formulation) of freshly prepared microcapsules were loaded onto a glass 173 
slide mounted to a calibrated scale. OM software (ToupTek Digital, Japan) capable of particle size 174 
analysis, microcapsule characterization, and morphological assessments was used to determine the 175 
basic characteristics of the microcapsules that are needed to complement the scanning electron 176 
microscopy (SEM) studies.     177 
Swelling Studies: To determine the swelling properties of the microcapsules (SA and PB-SA), 50 mg dry 178 
microcapsules were weighed and placed in 20 mL of two pH values (3 and 7.8) and two temperatures 179 
(25°C and 37°C) for 6 hours. The selection of the two temperatures, pH values, and study duration was 180 
based on our previously published work [14, 15]. The swollen microcapsules were then removed at 181 
periodically predetermined intervals (hourly).  The wet weight of the swollen microcapsules was 182 
determined by blotting them with filter paper to remove moisture adhering to the surface, 183 
immediately followed by weighing on an electronic balance.  All experiments were done in triplicate 184 
(n=3).  The swelling index of the microcapsules was calculated from the following formula [16, 17]: 185 
 186 
4. 𝑺𝒘𝒆𝒍𝒍𝒊𝒏𝒈 𝑰𝒏𝒅𝒆𝒙 =
𝑭𝒊𝒏𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕
𝑰𝒏𝒊𝒕𝒊𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕
  187 
 188 
Drug release studies (in-vitro dissolution test): A weighed sample (2 g) of PB loaded microcapsules 189 
was suspended in 200 mL of phosphate buffer solution at pH values of 1.5, 3, 6, and 7.8 for 6 hours, 190 
as appropriate.  The dissolution medium was stirred at 200 rpm. Sink conditions were maintained 191 
throughout the assay period [18, 19].  All the experiments were carried out at 25°C.  The absorbances 192 
of the solutions were measured every 30 minutes using a Hewlett Packard-based time controlled UV-193 
spec mounted with a close-loop flow system under sink conditions (Figure 1).  All analyses were carried 194 
out in triplicate (n=3).  Additionally, unloaded microcapsules (containing no drug) were analysed 195 
spectrophotometrically at λMax = 242nm using phosphate buffer at all four pH values (temperature 196 
maintained at 25°C) in order to exclude any interference in the analytical data and to ensure that only 197 
PB was being measured at that particular wavelength and experimental condition.  198 
 199 
 200 





Physical and chemical stability:   204 
The stability test was carried out by placing predetermined amounts of freshly prepared microcapsules 205 
onto sterile petri dishes (30 microcapsules in each) and storing them in thermostatically controlled 206 
ovens at -20°C, 5°C, 25°C, and 40°C respectively, with relative humidity set at 35% for 3 days.  The 207 
experiment was conducted using a stability chamber (Angelantoni environmental and climatic test 208 
chamber, Italy).  A temperature and humidity regulator was used to ensure constant experimental 209 
conditions. At the end of the experiment, the microcapsules were analyzed for any changes in 210 
appearance and morphology, and for the determination of the amount of drug remaining in each 211 
formula, using a validated UV-Vis stability-indicating method [20, 21]. Briefly, the dosage forms were 212 
crushed and dissolved in a 200 mL phosphate buffer at pH 7.8. The solution was filtered and the first 213 
20 mL were removed; and 10 mL of the filtrate were diluted to 100 mL in a volumetric flask. Then, 1 214 
mL aliquot of the prepared solution was transferred to 10 mL volumetric flask, and the volume was 215 
completed with the buffer. A calibration curve was constructed for PB in phosphate buffer across the 216 
concentration range of 0.01 mg to 4 mg/ mL with R2=0.99 (data not shown). Physical stability data 217 
(morphology and appearance) were recorded for both microencapsulated formulations (SA and PB-218 
SA), and chemical stability (drug content remaining) was recorded for the PB-SA formulation.    219 
 220 
Statistical analysis  221 
Values are expressed as means ± SD.  Drug content, production yield, and microencapsulation 222 
efficiency were assessed using Student’s t-test. Swelling index and drug dissolution comparison for 223 
the different formulations were also assessed and compared using Student’s test. The best fit model 224 
was derived using GraphPad Prism software (V6; GraphPad Software, Inc., USA). Statistical significance 225 
was set at p < 0.05 and all statistical analyses were performed using GraphPad Prism software.  226 
 227 
 228 
Results and Discussion 229 
Drug content, production yield, and microencapsulation efficiency: 230 
Significant levels of PB-loading (microencapsulation) efficiency were achieved for all microcapsules as 231 
shown in  232 
Table 1. The results of the drug content and encapsulation efficiency showed minimum variation 233 
among repeated samples, which confirms the reproducibility of our developed microencapsulation 234 
method. Additionally, high production yield with low variability in drug content and good drug loading 235 
efficiency were achieved.  Neither any peaks for a biodegradable polymer nor any alteration of the 236 
chromatographic pattern of PB was observed, which is in line with our published work.         237 
 238 
Table 1: Drug content, production yield, encapsulation efficiency, zeta potential, and mean particle 239 
size of SA and PB-SA microencapsulation formulations. 240 
 241 
Microcapsule size analysis and Zeta potential determination: 242 
Analysis of the size of the microcapsules obtained from each formulation, as demonstrated in  243 
Table 1, revealed uniform and consistent particle size distribution, and thus the addition of the drug 244 
did not alter the size of the microcapsules, ensuring effective encapsulation without adverse effects 245 
on size. SA and PB-SA microcapsules had an range in size of 0.8-1 mm. The significant uniformity in 246 
particle size distribution of the microcapsules ensures reproducibility.  247 
As depicted by Zeta potential values of -66mV (SA) and -72.9mV (PB-SA), the dispersion of 248 
microcapsules suggested a stable system [22], with the PB-SA formulation being more charged ( 249 
Table 1). This is assuming the higher charge (>25 mM) indicates stronger surface electrical charge of 250 
the suspended drug particles. Additionally, the PB-SA formulation would be more stable, given the 251 
greater repulsion created within the suspension system [23].  252 
 253 
Optical Microscopy: 254 
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From both formulations, SA and PB-SA, ten microcapsules were randomly selected for particle size 255 
and morphological analysis. Results show an overall consistent and uniform shape as determined via 256 
a calibrated scale mounted onto a glass slide. As evident in Figure 2, the mean diameter of SA 257 
microcapsules (Figure -a) (average ± SD) was 800 ± 20 μm, while that of PB-SA microcapsules (Figure -258 
b) was 850 ± 50 μm. Results obtained also include the horizontal diameter (L1), the vertical diameter 259 
(L2), and the microcapsule width (L3). 260 
 261 
Figure 2: SA microcapsule (a) and PB-SA microcapsule (b). L1 is the horizontal diameter, L2 is the 262 
vertical diameter, and L3 is the microcapsule width. 263 
 264 
Swelling studies: 265 
 266 
Figure  and Figure  show that the formulation type, the pH of the medium, and the temperature do 267 
have an effect on the swelling characteristics of the microcapsules. Evidently, the higher the 268 
temperature and pH, the more swelling of microcapsules in both formulations.  269 
In line with PB-SA in-vitro dissolution data (Figure ), the swelling index corresponds to degree of drug 270 
release. The greater the swelling, the higher the amount of drug that diffuses into the dissolution 271 
media. This is due to water uptake, expansion, and subsequent erosion of the alginate matrix, resulting 272 
in the loss of microcapsule structural integrity and release of both surface bound and encapsulated PB 273 
[24]. The swelling index is heavily influenced by pH and temperature, and, by considering physiological 274 
parameters, it is evident that at pH 7.8 and 37°C, the greatest swelling and thus the most extensive 275 
drug release occurs from PB-SA microcapsules. PB-containing microcapsules swell more than empty 276 
SA microcapsules. This could be due to the fact that the surface of PB-SA microcapsules contains dry 277 
crystal agglomerates compromising the surface integrity, causing weak links in the alginate matrix and 278 
easy expansion and rupture upon contact with water.  279 
By considering the swelling and dissolution data, it seems logical to emphasize the importance of the 280 
alginate matrix structural integrity and stability in order to ensure controlled drug release, particularly 281 
in physiological conditions. An important formulation excipient that should be considered for future 282 
work is a bile acid (BA), which has the potential to provide stability and matrix reinforcement [14]. 283 
Additionally, BAs have also been shown to be more hydrophobic than their corresponding salts, 284 
ensuring greater protection from water penetration as well as being very good tissue permeation 285 
enhancers in diabetes [25, 26].     286 
 287 
Figure 3: Swelling characteristics of PB-SA and SA microcapsules (pH 3 and 7.8) at 25°C.  288 
 289 
Figure 4: Swelling characteristics of PB-SA and SA microcapsules (pH 3 and 7.8) at 37°C.  290 
 291 
Drug release studies and in-vitro dissolution: 292 
Probucol release from the PB-SA microcapsules was studied in triplicates across four pH values (1.5, 293 
3, 6, and 7.8) at 25°C for a period of 6 hours each.  The selection of these four pH values was based on 294 
our previous studies examining the best sites of potential antidiabetic drug absorption in the 295 
gastrointestinal tract (GIT) [27-33]. However, the use of a gradient-pH system may have also provided 296 
good prediction of in vivo results. 297 
The release of PB was dependant on temperature and pH, which is in line with previous studies using 298 
SA-drug formulations [34, 35]. As shown in Figure , PB release was slow and minimal but in a relatively 299 
controlled manner at low acidic pH values (1.5 and 3).  As pH values were increased, the release of PB 300 
was also increased, in particular, at pH 7.8, which is expected [24, 36]. PB release from PB-SA 301 
microcapsules at pH 6 and 7.8 was biphasic and multiphasic, respectively (Figure ). This has important 302 
implications in diabetes therapy as work in our laboratory has confirmed the distal GIT to be the site 303 
of intended drug delivery due to an abundance of efflux transporters, which have been associated 304 
with PB absorption after oral administration, such as the transporter ABCA1 [37, 38]. However, the 305 
8 
 
exact impact of such release patterns in PB oral absorption, efficacy, and safety profiles remains 306 
difficult to predict [39-41].  307 
A possible explanation of the multi-phasic release of PB from the PB-SA microcapsules is that PB is 308 
unevenly distributed within the microcapsules, with some of it on the outside, as well as inside of the 309 
microcapsules. Thus, the multi-phasic drug release pattern depicted in PB-SA dissolution data (Figure 310 
) could be the preferential binding of PB to the microcapsule surface, and by coating the microcapsule 311 
surface, the drug would be quickly liberated following swelling and erosion of the alginate matrix.  312 
Preferential deposition of encapsulated drugs onto microcapsule surfaces has been extensively 313 
studied, and may occur due to several factors such as the hydrophilic-lipophilic balance of the surface 314 
(HLB), the molecular weight, solubility, and degree of ionisation of the drug, as well as the surface 315 
charge of the microcapsule and the physicochemical properties and proportions of the excipients used 316 
[42]. It is also possible that the rapid release of PB from the microcapsule surface is attributed to its 317 
very low solubility in the release medium (creating thermodynamic instability); as such, release 318 
mechanisms often stem from drugs that are very lipophilic and their release patterns are characterised 319 
by short “burst” times followed by much slower release concentrations [43].  320 
It appears that microencapsulation of PB using only the sodium alginate polymer results in drug 321 
coating of the surface by the drug, with some being distributed within the core of the microcapsule.  322 
Figure 5: Probucol release from PB-SA microcapsule over time across various pH values  323 
 324 
Accelerated stability studies (environmental chamber): 325 
Accelerated stability studies were carried out over a 3 day period, testing both formulations (SA and 326 
PB-SA) at -20°C, 5°C, 25°C, and 40°C and at a relative humidity of 35%.  327 
Both formulations (SA and PB-SA) appeared to retain their original morphological characteristics 328 
throughout the study. However, there were some changes in the colour, overall size, and quality of 329 
the microcapsule surfaces across the temperatures.  In detail, at -20°C, some PB-SA microcapsules 330 
formed agglomerates that were easily re-dispersed, while others retained their original shape. The 331 
appearance of PB-SA at this temperature was white and spherical following the 3 day period, with the 332 
original quality (soft microcapsules) maintained. Similarly, SA microcapsules were also soft, spherical, 333 
and flexible but were much lighter in colour (opaque in appearance). At the higher temperatures, 334 
microcapsules appeared to change colour from a white (5°C and 25°C) to a light brown (at 40°C), most 335 
likely due to oxidation of the alginate, whilst retaining their spherical shapes and even homogenous 336 
particle size distribution. In terms of size, it was evident that an increase of the temperature resulted 337 
in greater shrinkage (by up to 50%), of the microcapsules, with the biggest effect seen at a 338 
temperature of 40°C. This may be explained in terms of loss of moisture content, reducing the overall 339 
surface area and volume of each microcapsule. In addition, the microcapsules at all temperatures 340 
(except at -20°C) had become harder and more brittle owing to loss of moisture within the 341 
microcapsules and reduction in their elasticity.  342 
UV analysis of the microcapsules after three days of accelerated stability testing revealed an average 343 
% drug content of 2.6 ± 0.3 for PB-SA microcapsules, illustrating that various accelerated 344 
environmental conditions did not compromise drug content nor did it result in loss of drug structure. 345 
This complemented the visual characterisation of the microcapsules following accelerated stability 346 
testing and confirmed uniformity of drug contents. 347 
Conclusion 348 
Our vibrational-jet flow microencapsulation method of PB is effective in producing microcapsules with 349 
good stability and uniformity. However, the multi-phasic release characteristics may not result in 350 
optimised oral absorption. Thus, an interesting future investigation will be to incorporate BA as a 351 
formulation excipient, which may provide reinforcement to the alginate polymer matrix and enhance 352 
the controlled release of the drug, and perhaps optimise its potentials in T2D.    353 
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